Walgreens Boots Reports Strong Earnings and Revenue Growth
Walgreens Boots Shows Better Than Expected Earnings
Walgreens Boots (NASDAQ: WBA) has recently announced its fourth quarter earnings, shocking analysts with a positive EPS of $0.39. This figure surpassed estimates by $0.03, as analysts had predicted earnings of only $0.36. In tandem with this earnings growth, Walgreens also reported impressive revenues during this quarter that totaled $37.55 billion, exceeding the consensus estimate of $35.75 billion.
Future Guidance Looks Promising
Looking ahead, Walgreens Boots is setting its sights high for the upcoming fiscal year 2025. The company forecasts earnings per share (EPS) in the range of $1.40 to $1.80, although this is notably lower than the analyst consensus of $2.85. Moreover, it anticipates revenue between $147 billion and $151 billion, which is slightly above the analyst expectations of $145.60 billion.
Stock Performance Overview
As of the closing of the stock market, Walgreens Boots's shares were priced at $9.00. However, the company has seen a decline in its stock value over the past three months, with a drop of approximately -20.77%. In a more extended view, the stock has fallen by nearly -60.49% over the last 12 months. This volatility has resulted in multiple analyst revisions, with four positive EPS revisions contrasted against four negatives documented within the last 90 days.
Financial Health and Stability
An analysis from recent financial insights shows that Walgreens Boots's Financial Health score is categorized as "fair performance." This classification suggests that while there are challenges, the company is maintaining a level of performance deemed acceptable. It is essential for investors to keep an eye on relevant financial metrics as Walgreens Boots continues to navigate a competitive marketplace.
Additional Earnings Insights
Should you wish to dive deeper into Walgreens Boots's earnings performance, there are detailed reports available that break down their financial metrics and performance history. These insights can provide a clearer picture of where the company stands financially as it moves forward.
Key Takeaways for Investors
Investors should stay informed about Walgreens Boots’s strategies and performance updates moving toward the next fiscal year. Overall, understanding the earnings reports, future guidance, and tracking the company's stock performance can significantly aid in making informed investment decisions.
Frequently Asked Questions
What were Walgreens Boots's earnings per share for the fourth quarter?
For the fourth quarter, Walgreens Boots reported an EPS of $0.39, surpassing the analyst estimate of $0.36.
How much revenue did Walgreens Boots report?
The company's revenue for the quarter was reported at $37.55 billion, exceeding expectations of $35.75 billion.
What is the EPS guidance for Walgreens Boots for FY 2025?
Walgreens Boots has provided guidance for FY 2025 EPS in the range of $1.40 to $1.80.
How has Walgreens Boots's stock performed recently?
The stock recently closed at $9.00, reflecting a decline of -20.77% over the last three months and a significant -60.49% drop over the past year.
What is Walgreens Boots’s Financial Health score?
The company's Financial Health score is noted as "fair performance," suggesting that while there are challenges, the overall performance remains acceptable.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Investors Eagerly Await Banner's Earnings Announcement
- Significant Market Movement in France: CAC 40 and SBF 120 Decline
- Anticipating Earnings: Insights for Old Second Bancorp Investors
- Anticipating Earnings: First Community's Market Insights
- Anticipation Builds for Martin Midstream Partners Earnings Report
- Citi Maintains Neutral Rating for Bank of New York Mellon Amidst Strong Earnings
- Bold Sleepwear Collaboration: BedHead PJs and Bronwyn Newport
- Mizuho Upgrades Duke Energy: Strong Growth Potential Ahead
- Insights on the Evolving Landscape of Private Equity Deals
- Ipsos Revises 2024 Growth Outlook Amid Market Changes
Recent Articles
- Adapteo Group Earns 5 Stars in Latest GRESB Assessment
- Bank of America Surprises Investors with Strong Earnings Report
- Innoviva Specialty Therapeutics Announces IDWeek 2024 Presentations
- State Street Surpasses Q3 Earnings Expectations with Growth
- Digital Engineering Investments Reach New Heights by 2027
- Bank of America Surprises Everyone with Strong Financial Results
- MessageGears Unveils Innovative Data Activation Platform
- Mobileye Faces Challenges as RBC Downgrades and Lowers PT
- Sapiens Decision Unveils Underwriting Accelerator for Insurers
- Dianthus Therapeutics Showcases Innovative DNTH103 at AANEM
- Wells Fargo Optimizes Ardagh Metal's Stock Positioning Strategy
- AcuityMD Introduces Care Journeys to Transform MedTech Innovation
- Eupraxia's Breakthrough Osteoarthritis Treatment Shows Promise
- Fossil Group's Fresh Inducement Grant for New CEO Unveiled
- Montrose Environmental Group Awarded Major $249 Million Contract
- Empowering Black Breast Cancer Patients with Care for HER Initiative
- BioXcel Therapeutics Collaborates with UNC on ASD Research
- Future Growth of Orthopedic Surgical Robots Market Insights
- Amer Sports Set for Growth as TD Cowen Elevates Price Target
- Xylem Welcomes Meredith Emmerich as Applied Water Leader
- Analyst Maintains Optimism on Las Vegas Sands Stock Growth
- New Insights on Cartesian Therapeutics' Descartes-08 for MG Patients
- CNX Resources Surges Ahead with Technology and Market Insights
- Vivo Infusion Appoints Stephan Rodgers as New CEO
- Goldman Sachs Maintains Sell Rating on Plains GP Holdings (PAGP)
- Chemomab Therapeutics Reports Key Findings in PSC Treatment
- CECO Environmental Boosts Growth Potential with Credit Expansion
- Xanadu Mines Enhances Kharmagtai Project with New Reserves and Resources
- GCL Expands Leadership Team with Strategic New Appointments
- Viasat Enhances Digital Transformation with New Tech Partnership
- JPMorgan's Strong Q3 Performance Boosts Path Toward New Highs
- CECO Environmental Increases Credit Facility to $400 Million
- Ericsson's Stock Up as Strong Earnings Impress Investors
- Navigating Boeing's Challenges: A Potential Buying Chance
- MRC Global Takes Strategic Steps to Enhance Capital Framework
- Perion Network Schedules Q3 2024 Financial Results Call
- Navigant Credit Union Partners with Baker Hill for Efficiency
- Axsome Therapeutics Shares Anticipated Q3 Financial Highlights
- TopGum Unveils Innovative HoneyGum Line of Gummy Supplements
- Dianthus Therapeutics: DNTH103 Showcased at Neurology Meeting
- New Jersey Resources Plans Upcoming Earnings Call Details
- Exploring Top Investment Opportunities from Buffett's Portfolio
- Montrose Environmental Secures Major $249 Million Contract
- Exciting Findings from Cartesian's Descartes-08 Trial for MG
- Navigant Credit Union Enhances Loan Operations with Baker Hill
- Permian Resources Set to Reveal Q3 2024 Earnings Insights
- Advent Technologies' Q1 2024 Financial Performance Insights
- Atavistik Bio's ATV-1601: A New Hope for Cancer Patients
- Key Developments Unveiled by Climb Bio on Budoprutug
- Secura Bio Welcomes Chip Romp as New CEO to Propel Growth